$ATAI News
Last published 3mo ago
- 3mo agoHELPDFTXCMPSJNJ+1A CEO With a Proven Track Record of Success in Growing and Scaling Biopharmaceutical Companies Just Appointed CEO at a Clinical-Stage Biotech, Months Before Its Pivotal Phase 3 ReadoutGlobeNewswireNEW YORK, Aug. 05, 2026 (GLOBE NEWSWIRE) -- USA News Group News Commentary - In biotech, the gap between a promising drug and a commercial success is often bridged by a single thing: the operator who has done it
- 3mo agoATAIATAI Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Proposed Sale of AtaiBeckley to Eli LillyGlobeNewswireMONSEY, N.Y., July 28, 2026 (GLOBE NEWSWIRE) -- The Monsey law firm of Wohl & Fruchter LLP is investigating the fairness of the proposed sale of AtaiBeckley, Inc. (NASDAQ:ATAI) ("AtaiBeckley") to Eli Lilly
- 3mo agoHELPLLYATAICMPS+1Billions Flow Into Next-Generation Depression Treatments as Pharma Innovation AcceleratesPR NewswireMarket News UpdatesNews Commentary - Globally, Major Depressive Disorder (MDD) is a prevalent mental health condition that has seen an improvement in ...
- 3mo agoHELPLLYATAICMPS+2Big Pharma Just Paid Up to $3.8 Billion for Psychedelic Medicine, and the Rest of the Sector Is Being Repriced in Real TimePR NewswireFor half a century, psychedelic medicine was the field serious money would not touch. That ended this morning. Eli Lilly and Company (NYSE: LLY)...
- 3mo agoLLYATAIEli Lilly to buy psychedelics maker AtaiBeckley for $2.8 billion as experimental treatments gain tractionCNBCThe deal for AtaiBeckley gives Lilly access to experimental drugs based on DMT and MDMA.
- 3mo agoLLYATAILilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditionsPR NewswireEli Lilly and Company (NYSE: LLY) and AtaiBeckley Inc. (Nasdaq: ATAI), a clinical-stage biopharmaceutical company developing innovative therapeutics...
- 4mo agoATAIAtaiBeckley Doses Last Patient in VLS-01 Phase 2b TRD Study; Plans Phase 3 in Major Depressive DisorderGlobeNewswire156 patients randomized in multi-center, double-blind, placebo-controlled Phase 2b Elumina trial; topline data anticipated in Q4 2026 (ClinicalTrials.gov: NCT06524830)AtaiBeckley plans to advance VLS-01 into major
- 4mo agoATAIAtaiBeckley to Join the Russell Indexes, Expanding Visibility Across U.S. Equity MarketsGlobeNewswireAtaiBeckley to be added to the Russell 2000® Index and the broad-market Russell 3000® Index as part of 2026 reconstitutionThe Russell U.S. Indexes have approximately $12.2 trillion in assets benchmarkedInclusion expands
- 5mo agoATAIJEFFERIES GLOBAL HEALTHCARE CONFERENCE IN NEW YORK - AtaiBeckley Inc.Earnings Call TranscriptsI'm going to get started with the next session. I'm Andrew Tsai, Senior Biotech Analyst at Jefferies, and it's my pleasure to have Srini Rao, CEO of Atai Beckley, joining me today. Welcome, Srini. Thank you very much, An
- 5mo agoATAIAtaiBeckley Launches Patient Impact Grant Program for Mental Health Non-Profit OrganizationsGlobeNewswireThree $20,000 grants open to non-profit, mission-driven organizations working across community support, education and stigma reduction, and ecosystem innovation and independent research NEW YORK, May 28, 2026 (GLOBE
- 5mo agoATAIAtaiBeckley to Participate in Upcoming Investor Conferences in June 2026GlobeNewswireNEW YORK, May 27, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ:ATAI) ("AtaiBeckley" or "Company"), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting,
- 6mo agoATAIAtaiBeckley Reports First Quarter 2026 Financial Results and Provides Program and Business UpdateGlobeNewswirePhase 3 pivotal program initiation for BPL-003 in treatment-resistant depression on track for Q2 2026VLS-01 Phase 2 Elumina topline results anticipated in Q4 2026Consistent, convergent improvements demonstrated in EMP-01
- 6mo agoATAIAtaiBeckley and PsyPAN Receive a Silver Award in 2026 Patient Participant Index, Reflecting Ongoing Commitment to Participant-Informed ResearchGlobeNewswireNEW YORK, April 27, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ:ATAI) ("AtaiBeckley" or "Company"), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting,
- 6mo agoATAIAtaiBeckley Announces Additional Phase 2a Results for EMP-01 (oral R-MDMA) Showing Large and Consistent Improvements in Social Anxiety DisorderGlobeNewswireEMP-01 demonstrated a large, clinically meaningful reduction in patient-reported SAD symptoms at Day 43: placebo-adjusted LSMD -11.5 points (p=0.002) on SPIN; placebo-adjusted LSMD -15.6 points (p=0.004) on SAFE - a 38%
- 6mo agoAAPL.IXIC.SPX.RUT+6Apple's next CEO, Warsh's confirmation hearing, the psychedelic stock surge and more in Morning SquawkCNBCHere are five key things investors need to know to start the trading day.
- 6mo agoATAICMPSHELPDFTXHow Trump's psychedelics executive order could unlock stalled cannabis reformCNBCThe White House psychedelics executive order accelerates research, clinical trials and "Right to Try" access for drugs like psilocybin, MDMA and ibogaine.
- 6mo agoATAI25TH ANNUAL NEEDHAM VIRTUAL HEALTHCARE CONFERENCE - AtaiBeckleyEarnings Call TranscriptsGood afternoon, everyone. I'm Ami Fadia, biotech analyst here at Needham. Welcome to the next session with Atai Beckley. It's my pleasure to be hosting Srini Ra, who is the co-founder and CEO of the company. Srini, thank
- 7mo agoATAIAtaiBeckley to Participate in Upcoming Needham Healthcare ConferencesGlobeNewswireNEW YORK, April 14, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ:ATAI) ("AtaiBeckley" or "Company"), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting,
- 7mo agoATAIAtaiBeckley's BPL-003 Shows Rapid, Durable Antidepressant Response in Treatment-Resistant Depression Patients on SSRIs; Phase 2a Data Published in CNS DrugsGlobeNewswire66.7% of participants achieved an antidepressant response by Day 2 following a single intranasal dose of BPL-003 in both the 10 mg (n=6) and 12 mg (n=6) cohortsDurable responses observed at Day 85: 83% (5/6) (10 mg) and
- 7mo agoATAIAtaiBeckley Joins $3 Trillion CRSP Index and S&P Benchmark Indices Adding Mandatory Passive Fund Ownership to Phase 3 Pipeline CatalystGlobeNewswireInclusion in U.S. CRSP® benchmark indices triggers mandatory position-building by passive index funds tracking more than $3 trillion in AUM, including the world's largest mutual fundExpands market presence across
- 8mo agoATAILEERINK GLOBAL HEALTHCARE CONFERENCE - AtaiBeckley Inc.Earnings Call TranscriptsEverybody, thanks for joining us for our third day at the Learing Partners Conference in Miami. I'm Mark Goodman, one of the biopharm analysts. We're lucky to have Srini Rao, who is the CEO of Atai Beckley, for our next
- 8mo agoATAIBPL-003 Phase 3 Program Initiation on Track for Q2 2026 Following Successful FDA End-of-Phase 2 Meeting; AtaiBeckley Highlights Key Pipeline Milestones at 2026 Investor DayGlobeNewswireBPL‑003 holds Breakthrough Therapy Designation and is supported by positive Phase 2b results in treatment-resistant depressionCash runway reaffirmed through the planned early-2029 topline readouts from both parallel
- 8mo agoHELPCMPSATAIDFTX+1CNS Drug Developers Add Pharma Veterans as Sector Nears First FDA DecisionsPR NewswireThe central nervous system therapeutics sector is approaching a commercial inflection point as multiple candidates advance through late-stage trials...
- 8mo agoATAIAtaiBeckley Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business and Clinical UpdateGlobeNewswirePhase 3 pivotal program initiation for BPL-003 in treatment-resistant depression remains on track for Q2 2026 following successful End‑of‑Phase 2 meeting with the U.S. Food and Drug AdministrationOn-track for VLS-01
- 8mo agoATAIAtaiBeckley Announces Successful End-of-Phase 2 Meeting for BPL-003 in Treatment-Resistant DepressionGlobeNewswireAligned with FDA on dual-trial design Phase 3 program that aims to demonstrate robust efficacy and long-term safety and that allows for flexible dosingPhase 3 program initiation remains on track for Q2 2026BPL-003 was
- 8mo agoHELPATAIDFTXGHRS+1Psychedelic Biotechs Push Toward Phase 3: Five Companies Advancing CNS TreatmentsPR NewswireEquity-Insider.com News Commentary — Psychedelic compounds are edging closer to regulatory approval as pivotal trials in treatment-resistant...
- 8mo agoATAIAtaiBeckley Announces Positive Topline Results from an Exploratory Phase 2a Trial of EMP-01 (oral R-MDMA) in Social Anxiety DisorderGlobeNewswireEMP-01 met its primary objective on safety and tolerability, demonstrating a generally favorable and manageable safety and tolerability profileEMP-01 demonstrated a clinically meaningful placebo-adjusted least squares
- 8mo agoATAIAtaiBeckley To Host Virtual Investor Day on March 6, 2026GlobeNewswireNEW YORK, Feb. 20, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ:ATAI) ("AtaiBeckley" or "Company"), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting,
- 8mo agoATAIAtaiBeckley Appoints Michael Faerm as Chief Financial OfficerGlobeNewswireNEW YORK, Feb. 19, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc (NASDAQ:ATAI) ("AtaiBeckley" or the "Company"), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting,
- 8mo agoATAIAtaiBeckley To Participate in Upcoming Investor ConferencesGlobeNewswireNEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ:ATAI) ("AtaiBeckley" or "Company"), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting,
- 9mo agoATAIAtaiBeckley Participates in the 64th Annual ACNP Meeting with Two Scientific Poster Presentations and Hot Topic PresentationGlobeNewswireNEW YORK, Jan. 16, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ:ATAI) ("AtaiBeckley" or "Company"), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting,
- 10mo agoATAIAtaiBeckley Provides Update and Outlook for 2026 Ahead of J.P. Morgan Healthcare ConferenceGlobeNewswireNEW YORK, Jan. 08, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc (NASDAQ:ATAI) ("AtaiBeckley" or the "Company"), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing effective,
- 10mo agoATAIAtaiBeckley Completes Redomiciliation to the United StatesGlobeNewswireNEW YORK, Dec. 31, 2025 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ:ATAI) ("AtaiBeckley" or "Company"), a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective,
- 10mo agoATAINBIAtaiBeckley Added to the Nasdaq Biotechnology Index (NBI)GlobeNewswireNEW YORK and AMSTERDAM, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Atai Beckley N.V. (NASDAQ:ATAI) ("AtaiBeckley" or "Company"), a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by
- 11mo agoATAIAtaiBeckley Announces New U.S. Patent Granted for EMP-01, Strengthening Intellectual Property PortfolioGlobeNewswireNEW YORK and AMSTERDAM, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Atai Beckley N.V. (NASDAQ:ATAI) ("AtaiBeckley" or the "Company"), a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by
- 11mo agoATAIEnhanced Fortifies Executive Leadership Team & Board of DirectorsPR NewswireEnhanced, the elite sports competition and performance products company committed to giving athletes and people alike the ability to optimize their...
- 12mo agoATAIAtaiBeckley to Participate in the Jefferies Global Healthcare Conference in LondonGlobeNewswireNEW YORK and AMSTERDAM, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Atai Beckley N.V. (NASDAQ:ATAI) ("AtaiBeckley" or "Company"), a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by
- 12mo agoATAIAtaiBeckley Reports Third Quarter 2025 Financial Results and Recent Corporate HighlightsGlobeNewswireBPL-003 (mebufotenin benzoate nasal spray) granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA) for treatment-resistant depression (TRD) Reported positive topline data from the Phase 2b
- 1y agoATAIAtaiBeckley Announces Positive Topline Data from the Phase 2b Open-Label Extension Study of BPL-003, Supporting Safety and Efficacy of a Second Dose in Patients with Treatment-Resistant DepressionGlobeNewswireA 12 mg dose of BPL-003 (mebufotenin benzoate nasal spray) administered eight weeks after an initial 12 mg, 8 mg or 0.3 mg dose in the core study of the Phase 2b clinical trial produced additional rapid, clinically
- 1y agoATAIatai Life Sciences and Beckley Psytech Announce the Successful Completion of Their Strategic Combination to Create AtaiBeckley, a Global Leader in Transformative Mental Health TherapiesGlobeNewswireatai Life Sciences' shareholders voted to approve the strategic combination with Beckley Psytech Limited and the corporate redomiciliation at the Extraordinary General Meeting of Shareholders on November 4, 2025, with
- 1y agoATAIatai Life Sciences Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Common SharesGlobeNewswireNEW YORK and AMSTERDAM, Oct. 20, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ:ATAI) ("atai"), a clinical-stage biopharmaceutical company focused on transforming the treatment of mental health disorders, today
- 1y agoATAIatai Life Sciences Announces Pricing of Public Offering of Common SharesGlobeNewswireNEW YORK and AMSTERDAM, Oct. 16, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ:ATAI) ("atai" or "Company"), a clinical-stage biopharmaceutical company focused on transforming the treatment of mental health
- 1y agoATAIatai Life Sciences Announces Proposed Public Offering of Common SharesGlobeNewswireNEW YORK and AMSTERDAM, Oct. 16, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ:ATAI) ("atai" or "Company"), a clinical-stage biopharmaceutical company focused on transforming the treatment of mental health
- 1y agoATAIatai Life Sciences and Beckley Psytech Announce U.S. FDA Breakthrough Therapy Designation Granted to BPL-003, Underscoring its Potential in Treatment-Resistant DepressionGlobeNewswireBreakthrough Therapy designation recognizes the potential of BPL-003 to deliver substantial improvement over existing therapies for patients with treatment-resistant depressionFDA designation follows previously announced
- 1y agoATAIatai Life Sciences and Beckley Psytech Report Positive Phase 2a Data Demonstrating Improved Outcomes with a Two-Dose Induction Regimen of BPL-003 in Patients with Treatment-Resistant DepressionGlobeNewswireOpen-label study evaluated a two-dose induction regimen of BPL-003 (8 mg followed by 12 mg two weeks later) in patients with treatment-resistant depression and demonstrated rapid, clinically meaningful and durable
- 1y agoATAIatai Life Sciences Awarded Grant from the National Institutes of HealthGlobeNewswireNEW YORK and AMSTERDAM, Sept. 18, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ:ATAI) ("atai" or "Company"), a clinical-stage biopharmaceutical company on a mission to develop highly effective mental health
- 1y agoATAIAtai Life Sciences N.V. (ATAI) Presents at H.C. Wainwright 27th Annual Global Investment Conference TranscriptEarnings Call Transcripts
- 1y agoATAIatai Life Sciences to Participate in September Investor ConferencesGlobeNewswireNEW YORK and AMSTERDAM, Aug. 28, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ:ATAI) ("atai" or "Company"), a clinical-stage biopharmaceutical company on a mission to develop highly effective mental health
- 1y agoATAIatai Life Sciences Reports Second Quarter 2025 Financial Results and Recent Corporate UpdatesGlobeNewswirePlanned strategic combination with Beckley Psytech expected to solidify position as global leader in transformative, psychedelic-based mental health therapies with a short time in-clinic Reported positive topline data
- 1y agoATAIRecognify Life Sciences Provides Update on Phase 2b Trial of Inidascamine in Patients with Cognitive Impairment Associated with SchizophreniaGlobeNewswireInitial results demonstrate numerical improvement of cognitive and functional measures with inidascamine across both active treatment arms compared to placebo, but did not meet statistical significance on the primary